Premium
[Tris(pyrazolyl)methane]ruthenium Complexes Capable of Inhibiting Cancer Cell Growth
Author(s) -
Walker Jesse M.,
McEwan Alexis,
Pycko Roxanne,
Tassotto Mary Lynn,
Gottardo Christine,
Th'ng John,
Wang Ruiyao,
Spivak Gregory J.
Publication year - 2009
Publication title -
european journal of inorganic chemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.667
H-Index - 136
eISSN - 1099-0682
pISSN - 1434-1948
DOI - 10.1002/ejic.200900766
Subject(s) - chemistry , hela , tris , ruthenium , methane , medicinal chemistry , mtt assay , in vitro , stereochemistry , organic chemistry , catalysis , biochemistry
The [tris(pyrazolyl)methane]ruthenium complexes [(κ 3 ‐tpm)RuCl(solv) 2 ]PF 6 [tpm = tris(pyrazolyl)methane; solv = MeCN, dmso] and [(κ 3 ‐tpm)RuCl(LL)]PF 6 [LL = κ 2 ‐dppe, κ 2 ‐dppp, κ 2 ‐dppb, (PMePh 2 ) 2 ] have been prepared, characterized and screened in vitro for their antiproliferative properties against the MCF‐7 (breast) and HeLa (cervical) cancer cell lines by using the MTT assay. Although the MeCN and dmso complexes showed no activity under the conditions used, the phosphane complexes exhibited remarkable cytotoxic behaviour. (© Wiley‐VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2009)